Literature DB >> 11549915

Selective posterior rhizotomy and intrathecal baclofen for the treatment of spasticity.

C S von Koch1, T S Park, P Steinbok, M Smyth, W J Peacock.   

Abstract

Spasticity occurs in children and adults due to a wide range of conditions, including cerebral palsy, head and spinal cord trauma, cerebrovascular accidents and multiple sclerosis. Multiple treatment options have been described, including medical and surgical treatments. Medical treatments include intramuscular botulinum A toxin, oral baclofen and supportive bracing. Surgical approaches include selective posterior rhizotomy, intrathecal baclofen and orthopedic procedures to address deformities. Many reports have been published on these different treatment options, but rarely has a comparison been made between them. Therefore, this review is aimed at comparing selective posterior rhizotomy and intrathecal baclofen injection for spasticity due to cerebral palsy, especially in children. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549915     DOI: 10.1159/000050392

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  4 in total

1.  [Neuromodulation of spasticity in children by intrathecal baclofen].

Authors:  R Cumlivski; G Redl; W Strobl; W Girsch; A Krebs; P Machowetz
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

Review 2.  Selective dorsal rhizotomies in the treatment of spasticity related to cerebral palsy.

Authors:  Jean-Pierre Farmer; Abdulrahman J Sabbagh
Journal:  Childs Nerv Syst       Date:  2007-07-21       Impact factor: 1.475

Review 3.  Intrathecal baclofen for treating spasticity in children with cerebral palsy.

Authors:  Monika J Hasnat; James E Rice
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13

Review 4.  Neurosurgical Management of Childhood Spasticity: Functional Posterior Rhizotomy and Intrathecal Baclofen Infusion Therapy.

Authors:  Nobuhito Morota; Satoshi Ihara; Hideki Ogiwara
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-07-31       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.